TGTX Stock Analysis: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$53.94
-0.46 (-0.85%)
▼
5d:
+7.24%
30d:
+37.46%
90d:
+77.14%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.7/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: TGTX is 9.7% above its trading range ($49.18). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: TGTX is 9.7% above its trading range ($49.18). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$85.58
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$53.14
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $53.94, which is considered extended relative to its 30-day fair value range of $37.69 to $49.18. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.8) compared to its historical average (15.3). At these levels, the market is pricing in 7.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $41.55, while resistance sits at $57.38.
Market Sentiment: TGTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $48.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $41.55, while resistance sits at $57.38.
Market Sentiment: TGTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $48.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$37.69 -
$49.18
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
Protect Your Profits
TGTX is technically overbought (RSI 82). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+9.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 11.0% above Wall St target ($48.00)
- NEUTRAL: PE elevated vs history but 7.0% growth expectation is conservative given 300% recent growth
Trading Range Analysis
30-Day Trading Range
$37.69 -
$49.18
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$41.55
Resistance Level
$57.38
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.78
Wall Street Target
$48.00
(-11.0%)
Revenue Growth (YoY)
69.6%
Earnings Growth (YoY)
300.0%
Profit Margin
66.0%
Valuation Premium vs History
+7.0% premium
PE vs Historical
18.8 vs 15.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.0%
(market-implied from PE analysis)
1-Year Target
$57.72
(+7%)
2-Year Target
$61.76
(+15%)
3-Year Target
$66.08
(+23%)
3-Yr Target (if PE normalizes)
(PE: 19→15)
PE COMPRESSION
$53.83
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 87.1%)
$211.13
(+291%)
Base:
(SPY PE: 18.8, Growth: 87.1%)
$182.05
(+238%)
Bear:
(PE: 15.3, Growth: 87.1%)
$148.31
(+175%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 19.02 | Current EPS (TTM): $2.86
Bull Case
$60.10
(+11%)
Analyst growth 0.4%, PE expands to 20.9
Base Case
$54.63
(+1%)
Market implied 0.4%, PE stable at 19.0
Bear Case
$36.99
(-31%)
Severe decline -20.0%, PE contracts to 16.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 7:14 AM ET
Data refreshes hourly during market hours. Next update: 8:14 AM
Data refreshes hourly during market hours. Next update: 8:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
